Cargando…
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe
The CYP2C9 enzyme metabolizes a wide range of relevant drugs, among which are oral anticoagulants. VKORC1 is the pharmacodynamic target of the oral anticoagulants. The genetic polymorphisms CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A are the major determinants of the inter-individual variability in t...
Autores principales: | Buzoianu, Anca D, Trifa, Adrian P, Mureşanu, Dafin F, Crişan, Sorin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393720/ https://www.ncbi.nlm.nih.gov/pubmed/22863573 http://dx.doi.org/10.1111/j.1582-4934.2012.01606.x |
Ejemplares similares
-
The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018) -
Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014) -
CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation
por: Vesa, Stefan Cristian, et al.
Publicado: (2020) -
The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study
por: Forgerini, Marcela, et al.
Publicado: (2023) -
Polymorphism of the CYP2C9 and VKORC1 genes: a comment
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)